These new insights into the mechanisms of selective inhibition of oncogenic drivers provide critical information for cancers with increased MYC expression including multiple myeloma, Burkitt’s lymphoma, acute myeloid leukemia, and acute lymphoblastic leukemia. This evidence concerns the gene MYC and plasma cell myeloma.